SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " mace " 311 found 🔀 AI-powered Shuffle
Vivek Ramaswamy campaign ad for Ohio ‘shameful, disgusting’, says Republican congresswoman
Nancy Mace said: ‘This ad is going to go down as the most shameful, disgusting, offensive ad this election season’
Catawba Valley Health System opens Taylorsville Urgent Care
Catawba Valley Health System (CVHS) is pleased to announce the opening of Catawba Urgent Care of Mountain View in Taylorsville, effective Monday, October 19, 2026. Located at 50 Macedonia Church Road, Suite C, the new clinic becomes the fifth Catawba Urgent Care of Mountain View location. The Taylorsville location joins existing clinics in Sherrills Ford,…
Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027
Abbott Laboratories (NYSE:ABT) has announced plans to spin off its Nutrition division into a separate publicly traded company, with the transaction expected to be completed by the end of 2027, subject to regulatory and corporate approvals. The proposed separation would create an independent business focused on nutritional products while allowing Abbott to concentrate on its medical devices, diagnostics and established pharmaceuticals operations.
Swiss group agrees $390 million deal for medicines business with operations in North Africa
DKSH agrees to acquire NewBridge Pharmaceuticals in a $390 million deal, gaining a medicines platform with an established North African presence
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
Life Science Connect Acquires BrevisRefero to Expand Biopharma Outsourcing Technology Capabilities
Life Science Connect (LSC) has acquired Toronto-based BrevisRefero Corporation, a biopharmaceutical consulting firm and developer of the RFP>Navigator® platform, expanding... Read More
CAS collaborates with Microsoft to enable faster innovation in pharmaceutical, life sciences, and chemical industries
/PRNewswire/ -- CAS, a division of the American Chemical Society, today announced the availability of CAS Connections in Microsoft Copilot. The connector gives...
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
/PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative...
Democrats say Trump increased investments in drugmakers that were given Medicare exemptions
The report from congressional Democrats found that Trump’s pharmaceutical stock holdings grew from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025.
Trump increased investments in drugmakers that benefited from Medicare exemptions, Democrats say
WASHINGTON (AP) — Investments in pharmaceutical companies made on behalf of President Donald Trump increased significantly after he returned to the White House last year, with his portfolio adding mil...
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies,...
Halle Berry’s son cleared to testify in custody battle with Olivier Martinez
Actress’ ex-husband alleges she abused 13-year-old Maceo.
SK Life Science Supports SUDEP Awareness Efforts Through Partnership with CURE Epilepsy and The Cameron Boyce Foundation
/PRNewswire/ -- SK Life Science, Inc., a U.S. pharmaceutical company and part of SK Biopharmaceuticals, today announced its support of SUDEP awareness...
Daldrop Opens for Business in Southern Oswego County
$10 Million Facility in the L. Michael Treadwell Oswego County Industrial Park marks the largest expansion outside of Germany in the company’s 73-year history By Stefan Yablonski [caption id=attachment_11076 align=alignright width=450] Daldrop SBB CEO Jens Daldrop addresses attendees at the 2025 groundbreaking for the project. Daldrop also chairs the advisory board of Germany-based Daldrop Group.[/caption] A new era of cleanroom technology is underway in Central New York. The Daldrop Group’s advanced manufacturing facility and U.S. headquarters is physically built within the L. Michael Treadwell Oswego County Industrial Park. This industrial park is located in the town of Schroeppel. It marks the largest expansion outside of Germany in the company’s 73-year history. Daldrop SBB is based in Neckartailfingen, Germany. It is a global supplier of cleanroom technology, primarily to the pharmaceutical industry. It designs and builds advanced cleanroom environments for the pharmaceutical, biotechnology and medical technology industries. It nvested $10 million in the new project. “We broke ground in 2025; we were under construction all winter. We just opened this spring, early spring,” said Benjamin Morrow, operations manager and control. The company consolidated sites in Salina and DeWitt into the industrial park in Schroeppel, Morrow added. “The next move here is to maximize every square inch of this facility and then we are already looking at the expansion. So, it is more capital investment on equipment — definitely higher-end automation in additional equipment so we can produce more components and then to support the ever-growing base in North America,” Morrow continued. “We are the headquarters for service, maintenance and spare parts. So as Daldrop has more and more installations, they need more and more service, maintenance and spare parts. So that will come out of this facility as well — it already is.” “As a global leader in GMP (global manufacturing support) pharmaceutical cleanrooms for decades, I am very proud to bring manufacturing jobs to Upstate New York,” said Mike Sullivan, president of Daldrop US operations. Key to choosing Southern Oswego County [caption id=attachment_11077 align=alignright width=450] Daldrop SBB at the L. Michael Treadwell Oswego County Industrial Park when the company announced the start of construction.[/caption] Sullivan said that the selection of the Schroeppel industrial park was mainly due to the help of Operation Oswego County and two people in the organization. “Prior to being purchased by Daldrop International from the Stuttgart region of Germany, Vince Bongio was a founding partner in SBB Inc. as well as our head of engineering. We based out of Syracuse due to Vince’s skills in HVAC and the manufacturing capabilities found in Syracuse,” said Sullivan. Bongio moved to Syracuse from California in the 1970s to work in Carrier’s Industrial Division of Large-Scale Petrochemical Refrigeration. Next, he advanced to General Electric’s TV Tube Plant where he got into cleanrooms ,leading to his role of head of engineering for Clestra Cleanrooms where he met Sullivan, their New England distributor. “Vince Bongio is a phenomenal engineer. Formerly of Carrier, he grew up in California and went to Cal Poly,” Sullivan explained. “Carrier hired him right out of college and he moved to Syracuse. He is the reason we are in Syracuse today. He is retiring this year. We are very proud and his legacy is having brought Daldrop to Syracuse.” In 2000, Sullivan, Bazinet, Bongio Inc (SBB) was formed with engineering and manufacturing, based in Syracuse, and sales and construction based in Massachusetts as it is today. “SBB Inc. started in Syracuse. I had a design–build contracting firm out of Massachusetts that was primarily doing all the new technologies coming out of MIT,” Sullivan said. “I started a manufacturing side. A big thing for cleanrooms is the HVAC. Most cleanroom suppliers are architecturally focused people. The strength in Syracuse is HVAC. So, SBB developed with me running sales and construction out of Massachusetts and manufacturing out of Syracuse.” “Daldrop wanted to have a relationship in the States and of those who approached us, they were the only ones who really understood HVAC. So, we were the right fit for them. We did a joint venture focused out of Massachusetts from 2012 to 2018 leveraging their technologies,” Sullivan explained. “The commitment was if we brought their product to the States, we would do that if they built it here. “The pieces that had to be in place to make the investment, they wanted to acquire us, we were great with that. If you looked at business recommendations the general guidance was to build in a low labor area — something like North Carolina — but Syracuse had a strong background in HVAC and we chose Syracuse and Oswego County to be our headquarters in the States. So, it is built off of history, technology and the existing supply chain — bringing jobs back to the area.” During the initial discussions with Daldrop about coming to the U.S., SBB agreed to sell under the conditions Daldrop would manufacture in the U.S. There are many areas that offer incentives and economic packages, but the strength of HVAC expertise and skilled manufacturing was a big part of the discussions for site selection. Coming home [caption id=attachment_11078 align=alignright width=451] Construction moves forward in March at the L. Michael Treadwell Oswego County Industrial Park.[/caption] The second key person to building in Oswego County is Ben Morrow, Sullivan added. “Ben has been working with Daldrop SBB for more than 12 years and has advanced to COO of manufacturing and engineering. Ben grew up in Phoenix, so building a factory for the Germany company in Phoenix is a strong success for both his community and the appreciation of Ben’s skills as a team leader,” Sullivan said. “I went to high school in Phoenix. So, this is like full circle for me. It’s a small world,” Morrow said. “I hadn’t been back to Phoenix since graduation. This is one of the properties that John Trimble of C&S, he is the former president of C&S, he just retired, suggested. He and I were very good personal friends. John was from Mexico and I was from Phoenix. We knew each other from high school. And the architect of this building, Ed Smart of smartDESIGN Architecture in Batavia — I went to high school with him. So, this was a project that’s full circle a coming home kind of thing. The three of us knew each other — kind of like it was meant to be. Very serendipitous.” Schroeppel was one option for Daldrop to consider; the original intent was just to get a warehouse to store some product, he added. The facility is Daldrop’s largest outside of their native country. Total payroll at the facility will be approximately $2.4 million once fully staffed. “Here is 32,000 square feet and we plan to expand and put in an additional 10,000 square feet,” Morrow said. “We have 17.5 acres. We can put at least three more facilities here, just on this property. The master plan submitted for the current building is the first of possible three buildings on the campus.” “If we can find the right people and advance the production according to the plan, we should be able to grow for the next decade. One of the first jobs we filled was our new HR manager, with a primary focus posting and filling new positions,” Sullivan said. Stop the exodus, start hiring [caption id=attachment_11080 align=alignright width=452] Principals at the local Daldrop SBB headquarters, from left: Ben Morrow, Mike Sullivan and Jens Daldrop.[/caption] “I have been coming to Syracuse for 30 years. One of the things I had a hard time watching was the exodus of factories. One of the toughest things is to watch it with my partners’ kids who had to move away for jobs. It is important for us to give opportunity where people’s kids don’t have to leave the area to get work,” Sullivan said. “My responsibility is to find people who have skill sets that want to work and then I have to build opportunity for that work to happen. “After years of watching companies and Vince’s three sons all move out of the areas to get jobs, it is important to us to provide opportunities for the Syracuse region and help grow our company. We have been hiring for our new factory and will continue for the next few years.” “We are hiring and will continue to hire. Currently we have about 19 on staff right now,” Morrow said. “We expect to grow that by about 10 to 15 in the next 12 to 18 months or so. We are at 19 currently — one in the wings. It’s been great being able to hire locally. All these folks that we’ve been hiring, they all live within a few miles from here.” “We hired someone this past week (end of August). She grew up in the area, raised a family and is working down in Florida. She just took a job with us so she can move back and be with her family. We will be moving her back and she should be starting in October. We are very happy to see this happen,” Sullivan said. “I feel strongly about having a spot for the kids to not have to move out of the area. It is better to have people moving into the area.” Currently, Daldrop SBB has openings for finance manager, COO of construction and delivery, as well as mechanical, electrical designers and Revit modelers, construction managers, commissioning agents and many other skills that are needed. Along with Daldrop’s reputation in life science cleanrooms, there is a strong history in semiconductor, electronics, glass, photonics, aerospace and other markets. This may be helpful with any new technologies building in the market such as the Micron expansion and the support network, Sullivan said. “We acquired this property and closed on it two months before any announcement from Micron. It is serendipitous that they’re right down the street from us,” Morrow added. “Everybody started thinking ‘you guys are supporting Micron.’ We were here first. That is not a goal of ours. We may or may not … they are talking to us; it is an opportunity.” The long run [caption id=attachment_11079 align=alignright width=450] Benjamin Morrow, operations manager and control at Daldlrop, speaks during a recent ribbon-cutting event in Schroeppel.[/caption] “Long term, we will expand the Phoenix facility,” Sullivan said. “We built our facility with a campus approach. Sustainability is big. We designed our rooms to be more sustainable. Our building has no gas lines for heat. We put geothermal wells in the ground. We put heat pumps in for heating and cooling out of those wells and we put a large layer of solar panels up on the roof. We worked with National Grid for metering. Our building is a high efficiency model. We upgraded all the instillation and the glass filtering. So, it is a very green building. We will have a very minimal carbon footprint. It also adheres to LEED (Leadership in Energy and Environmental Design) construction standards.” “We are a bunch of HVAC engineers. We did a large scale geothermal and spent the money up front because we knew it made sense in the business sense in the environmental sense and sustainability,” Morrow said. “We have insulated metal panels on walls and roof; we are an envelope from the exterior.” Daldrop, as a global player, has a strong culture of sustainability that is found in all its products including the new facility. The building has been designed with (sixteen) 400-foot deep geothermal wells, high efficiency construction methods, approximately 70 kilowatt solar photovoltaic panels, electric vehicle chargers and 26% recycled content. “Daldrop thinks of long-term investing,” Sullivan said. “On the roof, photovoltaic panels supplement our power. Over half the energy that I use is coming from the sun. We have chargers up front for employee electric vehicles. This place is built to last. This slab that we are walking on, normal buildings are four inches, some go to six inches, we are nine inches all the way through — except where the heavy equipment is — that is 10 to 12 inches thick, solid concrete. It allows us to reconfigure for whatever type of equipment we want to bring in,” Morrow said. “We are authorized by Underwriters Laboratory to self-certify so we don’t need to have an inspector come out and recertify. We get audited often, but we certify our own electronics. The control system in this building is rather high-end. Our thermostat in every room is zoned, independent. We analyze the data; incorporate it with our solar panels.” “There is a lot of competition for people to work. It’s not just about how much salary they are going to make — it’s about the work environment, the ability for stability. We want to make sure our employees have the best environment to work in,” Morrow added. Similarities “One of the reasons I believe why Daldrop chose this area, Phoenix in particular, is because it is a village, a river-based village. Neckartailfingen in Germany where Daldrop is based is also a river-based village, manufacturing community. So, there is a lot of similarities — that smalltown feel,” Morrow said. “We have a lot of connections through multiple employees that lead back to Carrier, also. Everything came together, the timing everything.” “We are thankful for all the economic development support. Everyone has been helping make this happen. So, keep it up, it is working, that is all I got to say, Sullivan said. “If you look at historical industrial manufacturing, this region has skills that have been un-utilized. The northern industrial region has a lot of skills that if we can tap before they go away, we can leverage them. That is what we are trying to do. You’d be surprised at the supply chain left behind from Carrier — that supply chain is still there.” “Operation Oswego County has been fantastic,” Morrow added. “I can’t say enough good things about that group.” What Is Cleanroom Technology Cleanroom technology is a system of specialized engineering, filtration and operational controls used to maintain an extremely low concentration of airborne particles, microbes and chemical vapors. How It Works • Air Filtration: Uses HEPA or ULPA filters to remove 99.97% of tiny particles down to 0.3 microns. • Airflow Control: Directs air in a steady, unidirectional (laminar) or filtered turbulent pattern to push dust away from work areas. • Environmental Regulation: Maintains precise control over temperature, humidity and positive air pressure to block outside air leaks. • Specialized Attire: Requires personnel to wear full-body garments (“bunny suits”), gloves and masks to stop human shedding
AAPS names Patrick Sinko chief science officer
The American Association of Pharmaceutical Scientists (AAPS) has named Patrick J. Sinko, Ph.D., R.Ph., as chief science officer. Sinko will set the organization’s scientific strategy, guide scientific programming across in-person and digital platforms, and guide the direction of AAPS’s portfolio of peer-reviewed journals. Sinko, a pharmacist and pharmaceutical scientist, retains his academic appointment at Rutgers,…
AAPS names Patrick Sinko chief science officer
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
Concept Life Sciences appoints Dr Adrijana Vinter as Chief Executive Officer
We are pleased to announce the appointment of Dr Adrijana Vinter as Chief Executive Officer. Dr Vinter brings more than 20 years of experience spanning medicinal chemistry research, commercial development and executive leadership in the pharmaceutical and contract research industry sectors.
Small group health insurance market rates announced
Media Release, Office of Superintendent of Insurance (OSI) Santa Fe, NM – The New Mexico Office of Superintendent of Insurance (OSI) has approved 2027 health insurance premium rates for the small group health insurance market. As of March 2026, over 31,000 New Mexicans were enrolled in a small group plan. The average increase across small group plans is 19.8%. These rates take effect on January 1, 2027. The carriers offering small group coverage in New Mexico in 2027 are: Blue Cross Blue Shield of New Mexico (HealthCare Service Corporation) Presbyterian Health Plan Presbyterian Insurance Company UnitedHealthcare of New Mexico UnitedHealthcare Insurance Company Key Factors Driving the Rate Increases The primary factors that contributed to the 2027 increases are: Claims Experience - Higher than expected 2025 New Mexico claims experience, which is the foundation for the 2027 rate development. Cost Trend - Higher utilization and inflation impacted healthcare costs services, which impacts medical services and pharmaceutical costs nationwide. Risk Pool Changes - Nationwide, businesses with healthier employees are opting for alternative health coverage not under the Affordable Care Act (ACA). This results ina smaller and less healthy small group ACA risk pool. Final approved rates will be posted on the OSI website. To view the carrier rate sheets and rate increase specifics, visit the Office of Superintendent of Insurance website here. The Rate Review Process Conducted by OSI The OSI rate review process focuses on approving rates for health insurance plans that are actuarially sound, not excessive, inadequate, or unfairly discriminatory and ensuring health insurance rates comply with all state and federal laws. For more information, visit the Office of Superintendent of Insurance website at https://osi.state.nm.us/en/. *** About the Office of Superintendent of Insurance The Office of Superintendent of Insurance (OSI) is New Mexico’s regulatory agency responsible for overseeing a wide range of insurance products, including private health and life insurance, auto, home, business, and title insurance. OSI regulates private health plans in the individual, small group, and large group markets, ensuring that premium rates are fair, companies are financially sound, and health care insurance coverage is reliable. While OSI does not have authority over self-funded health plans, where an employer assumes the financial responsibility for paying employee health care claims, Medicaid, Medicare, or TRICARE, OSI plays a vital role in protecting consumers by reviewing premium rates, monitoring insurance company conduct, and licensing producers (formerly known as insurance brokers and agents).
Particle Engineering Takes Center Stage as Pharma Formulation Science Pushes Toward the Clinic
A forthcoming special issue of the Journal of Pharmaceutical Investigation will spotlight how particle engineering and formulation science are turning poorly soluble drug candidates into manufacturable medicines.
Particle Engineering Takes Center Stage as Formulation Science Pushes Drugs Toward the Clinic
A January 2027 special issue of the Journal of Pharmaceutical Investigation will spotlight how particle engineering and formulation science translate laboratory innovations into manufacturable drug dosage forms.
Particle Engineering Takes Center Stage as Journal Puts Drug Formulation Science in the Spotlight
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational particle engineering and formulation science, with submissions due June 30, 2026.
Full interview: Assembly Republican Leader Alexandra Macedo on High-Speed Rail, future of the party
Assembly Republican Minority Leader Alexandra Macedo, who recently stepped into her leadership role, shared her perspective on the challenges and priorities facing her caucus during an interview on California Politics 360, along with her call for accountability in the high-speed rail project.
Particle Engineering and Formulation Science Drive the Next Generation of Drug Delivery
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational advances in pharmaceutical dosage form development driven by particle engineering and formulation science.
Particle Engineering and Formulation Science Drive the Next Wave of Drug Delivery
A forthcoming special issue of the Journal of Pharmaceutical Investigation will gather research on how particle engineering and formulation science are transforming drug solubility, dosage form design, and pharmaceutical manufacturing.
Particle Engineering Takes Center Stage in Push to Translate Drug Formulation Science
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational advances in pharmaceutical dosage form development driven by particle engineering and formulation science, with submissions due by June 30, 2026.
Particle Engineering Takes Center Stage as Drug Formulation Science Enters Its Translational Era
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational advances in pharmaceutical dosage form development, covering particle engineering, solid-state control, QbD, and emerging manufacturing technologies, with submissions due June
Pharmaceutical innovation: a strategic investment in health and growth
Governments around the world are confronting increasingly common challenges: how to drive economic growth, address demographic changes and productivity pressures, and how to strengthen national resilience. Investment in health is fundamental to achieving these goals, and medicines and vaccines are central to this effort. We are at the cusp of the next golden age in...
Second UK health body drops Israeli drug firm after activist pressure
Decision by Royal College of Pharmacy to end sponsorship comes after concerns over Teva Pharmaceuticals’ ‘activities’
Life Is Asymmetric. The Scientists Who Figured Out Why Won the 2026 Nobel Prize in Chemistry
Henri Kagan and Kensō Soai designed chemical reactions producing only one of the two mirror-image forms of a molecule—an important finding for the synthesis of pharmaceuticals and other biological substances.
From 1800s to modern pharma: a Nobel-winning chemistry quest
Wednesday's Nobel chemistry prize crowned a series of advances that started in the 19th century and led to breakthroughs for modern pharmaceutical manufacturing.In 2001, US scientists William Knowles ...
AMO Pharma in Collaboration with Population Health Research Institute (PHRI) and Venca Research Inc. Announces FDA Advice on Potential Phase 3 Development Path for AMO-02 in Treatment of Arrhythmogenic Cardiomyopathy (ACM)
/PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with...
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Participants in the panel discussion include Dr. Christos Tzivinikos, and Pravin Chaturvedi, PhD, Napo's and Jaguar's Chief Scientific Officer and Chair of the Scientific Advisory Board.
Did New Science Board Just Shift BioCryst's (BCRX) Investment Narrative?
BioCryst Pharmaceuticals recently formed a seven-member Scientific Advisory Board made up of experienced rare disease and drug development leaders to guide its research, clinical plans and regulatory approach. The depth of this board, spanning big pharma R&D, AI driven drug discovery and rare disease commercialization, directly targets BioCryst’s execution risk as it builds a broader pipeline beyond its current portfolio. We will now examine how BioCryst Pharmaceuticals’ investment narrative...
'Flew Here Grew Here' talks trending entertainment topics
Olivier Martinez claims Halle Berry assaulted their 12-year-old son, Maceo, alleging she choked him and yelled "Who is dominant now?"
Hospital and pharmaceutical prices are smothering America’s businesses
Workers and employers are drowning in their health insurance premiums. The reason for that deluge: the health care industry’s high and inscrutable prices.
Bowie seizing Scotland shot after World Cup disappointment
BBC Scotland speaks to Kieron Bowie after he scored his first goal for his country against North Macedonia.
Emma Lees: Eight Years of Science, Patients and Progress
Emma Lees: Eight Years of Science, Patients and Progress / Biopharmaceutical Research, BMS, Bristol Myers Squibb, Cambridge Crossing, Cambridge Research,
Merck business unit opens R&D facility in Sheboygan Falls
EMD Electronics, the North America electronics business unit of Germany-based global health care and biopharmaceutical company Merck KGaA, today announced
True Religion to open its first Long Island location
True Religion is opening its first Long Island location at the Green Acres retail complex, joining Timberland and T-Mobile as new tenants in Valley Stream.
Olivier Martinez granted temporary restraining order against Halle Berry after accusing her of abusing their son
Olivier Martinez has been granted a temporary restraining order against ex-wife Halle Berry. He’s accused her of abusing their 12-year-old son, Maceo.
SpyGlass Pharma Acquires Advanced Vision Science, Securing Commercial IOL Supply, Accelerating Lens Portfolio Expansion
IRVINE, Calif.—SpyGlass Pharma, Inc. (Nasdaq: SGP), a late-stage biopharmaceutical company focused on transforming treatment paradigms for patients with chronic eye conditions, has announced the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL supply and accelerates lens portfolio expansion capability for SpyGlass Pharma, the announcement noted.
Halle Berry’s ex Olivier Martinez accuses her of child abuse, seeks restraining order
Olivier Martinez has accused his ex, Halle Berry, of abusing their 12-year-old son Maceo, and is seeking a temporary restraining order against her.
Wilson Sonsini Advises SpyGlass Pharma on Acquisition of Advanced Vision Science
On October 1, 2026, SpyGlass Pharma, a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions, announced the acquisition…
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
The portfolio comprises more than 15 proprietary brands and product lines and 10 branded generics across five product categories, sold in more than 40 countries through pharmacies, hospitals, retail chains and e-commerce. It is manufactured at GMP-certified facilities in Europe and the United States and supported by the Company's services in contract manufacturing, pharmaceutical distribution, telehealth and research and development.
Cardinal Health Extends CVS Health Pharmaceutical Distribution Agreement Through 2032
Cardinal Health (NYSE:CAH) has entered into a binding letter of intent to extend its pharmaceutical distribution agreement with CVS Health through June 30, 2032. The extended agreement will maintain the existing scope of distribution services provided by Cardinal Health to CVS Health.
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
OBIO marks $1bn funding milestone for Canadian health tech ventures
Life sciences and technology companies supported by the OBIO's CAAP have collectively raised more than $1bn in capital.
Light-driven nickel catalyst forms chemical bonds using less metal
Pharmaceuticals, fine chemicals, and agrochemicals are produced industrially using a wide range of chemical reactions. These processes need to become more efficient, less expensive, and more sustainable.
Swiss 'probably a league apart' from Scotland
Switzerland have "a ridiculously talented squad" who are "probably a league apart" from Scotland at present as the sides prepare to meet in the Nations League on Tuesday, according to football analyst John Walker. Following their 3-0 win in North Macedonia, Switzerland are the second test of Sebastien Pocognoli's reign as head coach after their 0-0 draw in Slovenia. "If Switzerland had faced the Scotland side in the first half, we wouldn't have had a second half we could have come back from," Walker said on the BBC's Scottish Football Podcast.
FTSE 100 rises as AstraZeneca lifts healthcare sector
London's FTSE 100 rose on Tuesday, lifted by pharmaceutical stocks after AstraZeneca agreed to take a $2 billion stake in Summit Therapeutics to advance cancer research.
1 in 7 Science Institute Dropouts Enter Medical Fields
1 in 7 Science Institute Dropouts Enter Medical Fields 418 of 2,939 dropouts from 2021-2026 advanced to medical/pharmaceutical sectors; lawmaker urges curriculum review
Why This Regeneron Rival Just Skyrocketed 90%
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' Eylea.
CPHI Milan 2026: Clinical data drives hair, mood, heart & cognitive health ingredients
Customers are increasingly opting for human data over hype. In this space, CPHI Milan 2026 will convene pharmaceutical and nutraceutical players who are
Elvedi stars as Switzerland keep North Macedonia at bay
Nico Elvedi played the full 90 minutes as Switzerland began their Nations League campaign with a comfortable 3-0 victory over North Macedonia in Skopje.The Leeds United defender, earning his 74th cap ...
Vega hails Yakin and Manzambi as Swiss head for Hampden
Former Celtic and Switzerland centre-half Ramon Vega says current national head coach Murat Yakin has "done a wonderful job" as he prepares to bring his side to Hampden Park on Tuesday. The Swiss opened with a 3-0 win on Saturday in North Macedonia, "which is not an easy place to go and they also have some good quality players". Vega pointed out that "Switzerland had a very good World Cup - one of their best in 70 years".
Swiss hail 'great job' without Xhaka & Embolo
Switzerland feel they did "a great job" of compensating for the loss of Granit Xhaka and Breel Embolo as they head to face Scotland on the back of an impressive 3-0 win in North Macedonia.
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
A legal feud unfolding in New York is putting a spotlight on the work of a business development veteran who is credited for pioneering one of biopharma’s hottest dealmaking mechanism: the China “NewCo” model. In a lawsuit originally filed in New York state court and recently moved to federal court, China’s Lepu Medical Technology has alleged that biopharma business development consultant Su Zhang, who was hired to help shop its GLP-1 weight-loss candidates to Western partners, engaged in corporate double-dealing and trade secret leaks. According to the complaint, while acting as Lepu’s primary dealmaking liaison for a group of obesity and metabolic disease drug candidates, Zhang was secretly double-dipping as the acting chief business officer for a direct competitor, BrightGene Pharmaceutical. “She never adequately disclosed the role, never sought Lepu’s consent, and never proposed any safeguard,” Lepu alleged in its complaint, which was filed in July after Zhang’s consulting firm, CoDevCo, sought certain transaction-based success fees from its angry customer through an arbitration process in Singapore. Lepu, the parent company of Lepu Biopharma, has asked Zhang to pay back its $500,000 retainer and disgorge all benefits she received during the alleged breaches of fiduciary duty, plus other damages and relief. The company has also requested the court grant injunctions to protect Lepu’s trade secrets. The ill-fated partnership officially kicked off in December 2024, when Lepu tapped CoDevCo as its “exclusive business development mechanism” to identify collaborators for the company’s drug candidates. According to Lepu’s complaint, Zhang personally negotiated and signed the agreement as managing director for CoDevCo, which used her home address. Before the Lepu deal, Zhang made a name following a short stint as the global head of business development for Hengrui Pharmaceuticals. It was during her tenure that Hengrui signed a landmark deal granting exclusive rights for a portfolio of GLP-1 assets to Hercules, which was at that time newly established by a group of private equity and venture capital firms. In addition to the regular upfront and milestone payments, Hengrui also gained an equity stake in Hercules, which later became Kailera Therapeutics. The Hengrui-Hercules deal opened a new paradigm, where a Chinese biopharma company spins off certain early-stage assets to investors for further development through the creation of a new company abroad. The “NewCo” model quickly came into vogue as it allows Western investors to access high-potential assets originating from China at an early stage while giving the Chinese licensors an opportunity to reap long-term benefits through equity stakes in the new firms. The NewCo model proved its value when Kailera staged a record-breaking $625 million IPO on Nasdaq this April, merely two years into the Hengrui deal. Related Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO On her LinkedIn page, Zhang described her work at Hengrui as “[b]uilding team and capability from the ground up,” forming NewCo and major pharma partnerships worth billions of dollars. Lepu clearly wanted that kind of track record to help boost its own cardiometabolic portfolio, which includes a range of assets for obesity, Type 2 diabetes, fatty liver disease and muscle preservation during weight loss treatment. “Lepu’s pipeline is very valuable, but only if Lepu could secure the right international partner to expand into the overseas market during the available commercial window,” the company argued in its complaint. The Chinese biotech said it had little knowledge of U.S. laws, customs or business practices in the business development field, and therefore “needed to rely entirely” on the expertise of Zhang and her team as the firm’s first engagement of a U.S.-based BD consultant. “Zhang’s dominating influence on the business development strategy is further evidenced by the fact that she personally controlled the business-development communications on behalf of Lepu with potential partners,” Lepu said in its complaint. After entering the deal, Zhang introduced Lepu to her four associates. According to Lepu’s version of events, all of them were allegedly employed at different time points to perform similar jobs at other Chinese companies that Lepu described as its competitors, while having access to Lepu’s confidential information. As such, Lepu described Zhang’s team as “a roster of individuals whose primary professional loyalty, by virtue of their concurrent full-time employment, ran to Lepu’s competitors.” As well as the specific examples set out in the case, a look at Lepu’s deals over the period suggests Zhang may have been involved in at least one transaction. During their partnership, Lepu, through its subsidiary Shanghai Minwei Biotechnology, also out-licensed its GLP-1/GIP/FGF21 agonist MWN105 to a NewCo called Sidera Bio in the fall of 2025. The deal included an upfront and near-term payment of $35 million, up to $1.01 billion in milestones, and a 9.99% stake in the Danish startup. It seems likely that Zhang facilitated the Minwei deal given that Lepu is on record as having used CoDevCo as its “exclusive business development mechanism.” The big shock for Lepu came in the form of a news article on June 25, 2025. The article, reporting on phase 2 data for BrightGene’s GLP-1/GIP receptor agonist BGM0504, identified Zhang as acting chief business officer of the Lepu rival. Blindsided by her association with BrightGene, Lepu confronted Zhang in July 2025. “Lepu was given assurances that there was nothing to be concerned about and told that Zhang would explain the matter to Lepu,” Lepu alleged in its complaint. “Zhang never did.” Lepu claimed that Zhang had the motive and opportunity to steer potential prospective partners toward BrightGene or other competitors. Later, in February 2026, one of Zhang’s associates joined BrightGene as the vice president for global business development, according to the complaint. Around the same time, Lepu sent written demand letters asking Zhang to account for her BrightGene role, identify what confidential data were shared with the rival firm, and provide any conflict-of-interest or firewall policies during the engagement. According to Lepu, neither CoDevCo nor Zhang answered the questions in their responses. Related Novo vs. KBP: How a $1.3B deal turned into a fraud accusation and an international legal fight In a motion to dismiss filed with the U.S. District Court in the Eastern District of New York on Sept. 4, Zhang’s legal team argued that Lepu’s agreement was signed with CoDevCo, and that an employee of the contractor does not owe fiduciary duties to the client. In its complaint, Lepu said: “That CoDevCo was the contracting entity does not insulate Zhang from personal liability for duties she personally undertook and personally breached.” Taking the argument one step further, the defending party argued that the consulting agreement “does not create a fiduciary relationship even between CoDevCo and Lepu; instead, it identifies CoDevCo as an independent contractor retained to market Lepu’s business to potential western partners.” Although CoDevCo was Lepu’s exclusive business-development contractor, there were no terms stipulating that the consulting firm should serve only Lepu, Zhang’s lawyer noted. As to Lepu’s claims that Zhang misappropriated trade secrets, the defendant argued that Lepu authorized the use of the information so Zhang’s team could perform their service per the agreement. In a rebuttal filed on Sept. 11, Lepu’s lawyer set out why they believe the Chinese biotech satisfied New York law’s misappropriation definition by alleging that the defendant used a trade secret “in breach of a duty or through improper means.” As an alternative to dismissing the suit, the defendant suggested the action should be stayed pending outcomes from the arbitration of a separate case in Singapore. While NewCo pioneer Zhang is defending her business arrangements, momentum behind the NewCo trend has continued unabated into 2026. Through August, Chinese biotech assets have spurred 15 NewCo deals this year, according to local trade publication PharmaDJ.
Intense Media Pressure an Emerging Challenge in CHO Business
Growing culture media requirements are becoming a major logistical and storage challenge for biopharmaceutical manufacturers.
Oracle Adds Domain-Trained AI to Life Sciences Data Intelligence Platform
Natural-language, domain-aware AI capabilities and expanded analytics tools enable pharmaceutical research teams to explore real-world data and generate traceable, decision-ready evidence ORLANDO, Fla., Sept. 24, 2026 — Oracle Life Sciences Data Intelligence now combines real-world data, domain-trained AI capabilities, and advanced analytics in a single connected intelligence platform, helping pharmaceutical research teams move from questions […]
Branded Pharmaceuticals Stocks Q2 In Review: Phibro Animal Health (NASDAQ:PAHC) Vs Peers
Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnin...
Merck Life Science Expands Bengaluru Manufacturing with €13 Million Investment
Merck Life Science is expanding its manufacturing capabilities in Bengaluru with an investment of approximately €13 million, strengthening the company’s ability to supply critical materials to customers across India and the wider Asia-Pacific region. The expansion at Merck Life Science’s Jigani site in Bengaluru will introduce biological buffer manufacturing alongside the facility’s established chemistry capabilities. The investment is designed to enable faster and more reliable access to critical materials used by customers across research, diagnostics, biotechnology and biopharmaceutical manufacturing. The development further advances Merck Life Science’s “in-region, for-region” approach, under which the company is expanding manufacturing capabilities closer to the markets and customers it serves. By adding biological buffer production in India, the Jigani expansion will broaden the site’s manufacturing capabilities while strengthening Merck Life Science’s regional supply infrastructure for the rapidly developing life sciences sector across India and Asia-Pacific. The company said the expansion reflects both the contribution of its teams and its collaboration with government and industry stakeholders. Merck Life Science acknowledged the support of India’s Department for Promotion of Industry and Internal Trade (DPIIT), the German Embassy New Delhi, and Invest India in helping strengthen life science manufacturing capabilities in the region. The investment comes as India continues to expand its role across pharmaceutical, biotechnology, diagnostics and biomanufacturing value chains, increasing demand for dependable regional access to materials supporting research and manufacturing operations. The Bengaluru expansion reinforces Merck Life Science’s focus on building manufacturing capacity within Asia-Pacific and supporting customers through a more regionalised supply network.
Jaguar Health Receives Fee Waivers from FDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Pres
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Supports Optimi’s planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSDVANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer. Dr. Blough has significant experience leading Health Ca
Hanx Biopharmaceuticals (Wuhan) Enters Agreement To Explore AI For Science In Drug Research
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKEX:3378:
Transformative Biological and Environmental Frontiers: Synthesizing the 2026 Tang Prize Science Laureates
The Tang Prize in Sustainable Development and Biopharmaceutical Science honors pivotal scientific advances that improve global health, restore damaged ecosystems, and deliver transformative medical treatments. The 2026 science laureates, Professor Susan Solomon for Sustainable Development, along with Dr. Steven A. Rosenberg, Dr. Michel Sadelain, and Dr. Carl H. June for Biopharmaceutical Science, demonstrate how disciplined
Czech PM targets medicine prices in new bid to cut healthcare costs
The pharmaceutical industry warns that medicines already account for a declining share of healthcare spending, arguing that efficiency gains should also be sought in other areas
Can Democrats flip House seat in SC? Navy official fired by Hegseth faces Charleston councilwoman.
Democrats think they have a shot at picking up South Carolina’s 1st Congressional District in the Lowcountry after two straight thumpings from retiring U.S. Rep. Nancy Mace.
MU Health Care earns national recognition by SNMMI
(9/18/26) MU Health Care has been designated a Clinical Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Syneos Health and Tufts CSDD Study Shows Clinical Trial Performance Depends More on Operating Model Design Than Sourcing Strategy
Data From 13 Leading Pharmaceutical Companies Points to Execution, Governance and Partner Coordination as Key Drivers of Trial PerformanceMORRISVILLE, N.C., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced findings from a first-of-its-kind benchmarking study conducted by the Tufts Center for the Study of Drug Development. The research examined one of the industry’s most persistent questions: does the sourcing
DHL inks health care logistics deals in South America
Parcel giants have been investing in health care and pharmaceutical shipping, among their most lucrative lines of business.
Three UConn School of Pharmacy Alumni will be recognized at the 2026 UConn School of Pharmacy & Pharmaceutical Sciences Alumni Awards
The 2026 UConn School of Pharmacy & Pharmaceutical Sciences Alumni Awards take place on Saturday, September 19, where three alumni will be recognized fo ...
AbbVie named Official Pharmaceutical Sponsor of PGA TOUR, 2026 Presidents Cup; launches Birdies for Brain Health campaign
NORTH CHICAGO, Ill.– AbbVie (NYSE: ABBV), a global pharmaceutical leader, and the PGA TOUR announced Tuesday a partnership naming AbbVie the Official Pharmaceut
Novo Nordisk (CPSE:NOVO B) Rebrands As Novo In Consumer Health Push
Novo Nordisk (CPSE:NOVO B) has rebranded to "Novo" as part of a shift toward a more consumer-focused healthcare identity. The group is introducing a new corporate culture intended to support its obesity and diabetes franchises in increasingly crowded markets. Management positions the rebrand as a move beyond traditional pharmaceuticals, with a broader focus on consumer-facing health solutions. The shift to the Novo identity reworks how the business presents itself to obesity drug users and...
BioMarin appoints Robert Plenge to its Board and Science & Technology Committee
BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors and to the Science and Technology Committee, effective September 10, 2026.Original SEC Filing: BIOMARIN PHARMACEUTICAL INC [ BMRN ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…
What supplement formulators can borrow from pharmaceutical delivery science
Poor absorption is a problem the pharmaceutical industry solved decades before most supplement formulators had to think about it. Compounds that show real biological activity in a lab often perform far worse once they're inside the body, because getting a molecule to dissolve, cross the gut wall and reach circulation is a separate engineering problem from proving the molecule does something useful
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports
GE HealthCare Technologies is in talks over a possible $1 billion deal to buy radiopharmaceutical developer Sofie Biosciences, the Financial Times reported on Sunday citing people familiar with the matter.
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
* 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories * Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio * Cumulative contract manufacturing orderbook increases to more than 27.
What Health Equity Champions Can Learn from Pharmaceutical Sales
The same mechanics can now help people meet new Medicaid work requirements or exemptions, increase referrals to evidence-based health interventions, and dramatically increase enrollment in vital programs that improve health outcomes and reduce inequities.
Lilly’s GLP-1 Windfall to Fund Investments in Women’s Health
The pharmaceutical giant has been assembling experts and hunting for new medicines across conditions including bone health and endometriosis, sources told Bloomberg.
Browns cornerback Denzel Ward joins Guardians’ ownership group
The Macedonia native is the second prominent athlete from Northeast Ohio to buy a stake in the Guardians this year, joining Travis Kelce.
Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
/PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a...
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held September 14-16, 2026, at the Lotte New York Palace Hotel. A Company presentation will be available on demand here beginning Friday, Septem
Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
/PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering...
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]
People on the Move: Leo Russo, PhD, Joins Life Science Cares Philadelphia Board of Advisors
Life Science Cares Philadelphia has welcomed Leo Russo, PhD, to its Board of Advisors, bringing more than 25 years of pharmaceutical industry experience in…
From Pandemic Prevention to Pharmaceutical Resilience: Why Health Security Should Be Part of US-Taiwan Economic Security Cooperation
As strategic competition in the Indo-Pacific region intensifies, Washington increasingly views Taiwan as both a reliable partner for democracy and regional stability, and as a critical contributor to supply-chain resilience and technology security. However, one important area has room for improvement: health security and pharmaceutical resilience.
Women in Science: Dr Sabina Auhunas - TIB-Blog
The blog series “Women in Science” introduces women from the TIB who give insights into their careers and personal experiences in science. Dr Sabina Auhunas studied Pharmacy at Bogomolets National Medical University, and obtained her PhD in Pharmaceutical Sciences at Shupyk National Healthcare University of Ukraine in Kyiv and is now working at TIB (Open Science Lab). In this interview, she talks about diversity, shifting directions and persistence in academia.
WATCH: Trump says more pharmaceutical companies will lower drug prices
A winner, a loser, and a mid-stage signal from a major cardiology research conference
The mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from Morning Rounds
UToledo College of Pharmacy and Pharmaceutical Sciences Welcomes Largest Pharm.D. Class in 5 Years
White Coat Ceremony marks the start of the professional journey for 135 incoming pharmacy and pharmaceutical sciences students.
Thyroid medication recalled nationwide due to possible ‘superpotency’ issue
A pharmaceutical company is recalling 3,655 thyroid tablets sold nationwide because they could be more potent than usual and may bring about health issues for people who use them.
Enough with the podcasts. We elected politicians, not influencers.
Nancy Mace posed in a bikini. Gavin Newsom launched a podcast. AOC and Bernie Sanders are TikTok stars. Can they start doing the jobs we pay them for?
Moving science out of silos: A conversation with biochemist and philanthropist Mick Hitchcock, Ph.D.
Biochemist Mick Hitchcock reflects on his career in pharmaceutical innovation and his commitment to advancing science and communication at the University of Nevada.
How SC’s Mace, Wilson repaired relationship after bruising start in GOP primary
Attorney General Alan Wilson is the 2026 Republican nominee for South Carolina governor. U.S. Rep. Nancy Mace finished fifth in the primary and endorsed Wilson.
Chuck Stevens named president of RTI Health Solutions
RTI Health Solutions names Chuck Stevens as president, bringing more than 25 years of biopharmaceutical and life sciences leadership experience.
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today...
Human creativity still has the edge – and this CEO says an MBA can help you use it
Emerging technologies are changing the face of Australian business, but this pharmaceuticals CEO says there’s still plenty of room for human creativity, if you’ve got the right tools